NEW YORK (GenomeWeb) – In a prospective study, Mayo Clinic researchers have sequenced samples from breast cancer patients who did and who did not respond to chemotherapy to find that both groups harbored similar common genomic alterations.

As part of the Breast Cancer Genome-Guided Therapy (BEAUTY) study, the researchers analyzed genetic variants present in tumors from some 140 patients, some of whom experienced a pathological complete response and some of whom did not, and developed mouse avatars for a subset of patients.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Oct
23
Sponsored by
PerkinElmer

This webinar will address a range of methods for optimizing small RNA library preparation.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.  

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov
07
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a leading pathology lab implemented a next-generation sequencing panel to capture comprehensive molecular tumor profiles.